Development of a Protocol for Obtaining a Homologous Cell Product of Animal Origin Intended for Preclinical Studies of Antitumor Vaccine CaTeVac

• Published in: Bulletin of experimental biology and medicine Vol. 176; no. 6; pp. 806 - 810
• Main Authors: Nekhaeva, T. L., Laskov, I. D., Fedoros, E. I., Danilova, A. B., Efremova, N. A., Emelyanova, N. V., Blokhina, M. L., Grigoryevskaya, A. V., Baldueva, I. A.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.04.2024; Springer Nature B.V
• Subjects: Adoptive immunotherapy; Antigens; Antitumor activity; Biomedical and Life Sciences; Biomedicine; Bone marrow; Cancer vaccines; CD11c antigen; CD80 antigen; CD83 antigen; CD86 antigen; Cell Biology; Cell differentiation; Clinical medicine; Correspondence; Dendritic cells; Drug development; Growth factors; Humidity; Immunotherapy; Internal Medicine; Laboratory animals; Laboratory Medicine; Medical research; Morphology; Oncology; Pathology; Physical characteristics; Research centers; Transgenic animals; Vaccines; biomedical cell product; dendritic cells; preclinical studies; relevant models; experimental oncology
• ISSN: 0007-4888; 1573-8221; 1573-8221
• DOI: 10.1007/s10517-024-06113-z

When developing a program of preclinical studies of human cell-based drugs intended for adoptive immunotherapy of cancer patients, the biological effect should be substantiated by data describing their immunological action. Administration and study of human autologous dendritic cell vaccine to immunocompetent animals are not adequate in terms of immunological compatibility. It is possible to use immunocompromised, knockout, or transgenic animals or to obtain a homologous cellular product, namely, a preparation based on animal cells using a technology similar to obtaining the original preparation for clinical practice in humans. Within the framework of this study, we have developed a protocol for obtaining a homologous cell product based on animal dendritic cells (mice, rats) according to a similar technology for obtaining human vaccine dendritic cells, and demonstrated the comparability of morphological characteristics and expression of differentiation antigens of dendritic cells (CD11c, CD80, CD86, and CD83) of animals (mice) and humans.